Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Teva
Deloitte
Cerilliant
Cipla
Fuji
McKinsey
Chinese Patent Office
Daiichi Sankyo

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLUOCINOLONE ACETONIDE

« Back to Dashboard

Clinical Trials for Fluocinolone Acetonide

Trial ID Title Status Sponsor Phase Summary
NCT00008515 Fluocinolone Implant to Treat Macular Degeneration Completed National Eye Institute (NEI) Phase 1 This study will test the safety and effectiveness of a fluocinolone implant to treat age-related macular degeneration. This eye disease can severely impair central vision, affecting a person's ability to read, drive, and carry out daily activities. It is the leading cause of vision loss in people over age 60. The fluocinolone implant is a tiny plastic rod with a pellet of the steroid fluocinolone on the end. The pellet slowly dissolves and releases the medication into the fluid in the eye. Vision loss in macular degeneration is caused by the formation of new blood vessels in the choroid-a thin, pigmented vascular layer of the eye behind the retina. These abnormal vessels leak blood under the macula, the part of the retina that determines central vision. Tissue studies show evidence of inflammation in the retinas of patients. This study will test whether the slow release of the steroid fluocinolone directly into the affected part of the eye can prevent or slow further vision loss. Preliminary animal and human studies with fluocinolone implants have shown some benefit in reducing blood vessel growth and improving or stabilizing vision. Patients 50 years of age and older with age-related macular degeneration may be eligible for this study. Study patients will be randomly assigned to one of two treatment groups. One will receive a 0.5-mg dose implant; the other will receive a 2-mg dose implant. Theoretically, the implants can release the medicine for 2 to 3 years. Participants will have a medical history, physical examination and complete eye examination. The latter will include a vision test, eye pressure measurement, examination of the pupils, lens, retina, and eye movements. Photographs of the eye will be taken with a special camera. Patients will also undergo fluorescein angiography, a test that takes pictures of the retina using a yellow dye called sodium fluorescein. The dye is injected into the blood stream through a vein. After it reaches the blood vessels of the eye, photographs are taken of the retina. When the above tests are completed, patients will be scheduled for surgery to place the implant. The procedure will be done under either local or general anesthesia. Follow-up visits will be scheduled 1, 2, 4, and 6 weeks after surgery, then at 3 and 6 months after surgery, and then every 6 months until the implant is depleted of medicine or is removed. Several of the exams described above will be repeated during the follow-up period to evaluate the treatment and side effects, if any.
NCT00132691 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed National Eye Institute (NEI) Phase 4 The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
NCT00132691 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed JHSPH Center for Clinical Trials Phase 4 The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
NCT00344968 Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema Completed Alimera Sciences Phase 3 This study will evaluate the safety and efficacy of an intravitreal insert of fluocinolone acetonide for the treatment of diabetic macular edema.
NCT00407082 Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants Completed Bausch & Lomb Incorporated Phase 2/Phase 3 This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (FA) intravitreal implants for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye. An additional objective is to compare the safety and efficacy of two doses of fluocinolone acetonide.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Fluocinolone Acetonide

Condition Name

Condition Name for Fluocinolone Acetonide
Intervention Trials
Diabetic Macular Edema 7
Posterior Uveitis 3
Panuveitis 3
Intermediate Uveitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Fluocinolone Acetonide
Intervention Trials
Uveitis 10
Macular Edema 9
Edema 8
Uveitis, Posterior 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Fluocinolone Acetonide

Trials by Country

Trials by Country for Fluocinolone Acetonide
Location Trials
United States 74
India 16
United Kingdom 2
Australia 1
Hungary 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Fluocinolone Acetonide
Location Trials
Maryland 7
North Carolina 5
Massachusetts 5
Texas 4
Georgia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Fluocinolone Acetonide

Clinical Trial Phase

Clinical Trial Phase for Fluocinolone Acetonide
Clinical Trial Phase Trials
Phase 4 8
Phase 3 7
Phase 2/Phase 3 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Fluocinolone Acetonide
Clinical Trial Phase Trials
Completed 15
Terminated 4
Active, not recruiting 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Fluocinolone Acetonide

Sponsor Name

Sponsor Name for Fluocinolone Acetonide
Sponsor Trials
Alimera Sciences 7
Bausch & Lomb Incorporated 6
Johns Hopkins University 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Fluocinolone Acetonide
Sponsor Trials
Industry 23
Other 9
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKinsey
Fuji
Cerilliant
Dow
Harvard Business School
Argus Health
Teva
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.